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Patients with solid cancers lose weight and 
have decreased appetite, early saturation 
and nausea mainly related to the tumour 
burden  (Ravasco et al, 2003), but also 
correlated to intake deficits (Ravasco et al, 
2007). Comparable results are not 
available in haematological cancers, but at 
least during the cytotoxic therapy it is the 
clinical experience, that the nutritional 
problems are even more pronounced than 
in patients with solid cancers. In patients 
with malignant haematological disease 
Abstract 
 
Background: Several studies have indicated that cancer patients have significantly altered 
taste sensitivity without specifying the preferences. One of the related problems is low 
compliance to nutritional therapy with oral nutritional supplements (ONS) in patients 
suffering severe weight loss. Objective: We wanted to investigate taste preferences and 
sensoric characteristics among three usually used ONS in patients with malignant 
haematological disease during cytotoxic treatment.  Design: Tested drinks were: Protin® 
(protein-enriched-milk, ARLA), Nutridrink® (NUTRICIA) and hospital-produced drink of 
buttermilk and egg (RH-drink), all with vanilla taste. Protein-contents were the same (5-6 
g/100 ml). Forty-one consecutive patients tasted the three ONS in a randomized, blinded 
set-up with one of the ONS included twice as a control. Taste qualities were quantified on 
VAS-scales: Bitter, sweet, salt, sour, metal, gritty, consistence and ability to drink 150 ml 
(one glass), and the patients arranged the drinks in order of preference. Results: The 
sensory qualities differed significantly concerning sweet (p<0.05), sour (p<0.008) and the 
ability to drink 150 ml. Patients preference order was Protin® (p<0.002) as the best, RH-
drink next (p<0.005) and Nutridrink® last. Conclusions: Patients in cytostatic therapy had 
clear preferences for fresh, hyperosmolar, milk-based ONS without vitamins, and had major 
difficulties with a commercial product. The preferences were not related to osmolarity.  
 
Keywords: Oral nutritional supplements, malignant haematological diseases, taste, 
compliance   
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with high-dose chemotherapy and often 
stem-cell transplantation, changes in taste 
and smell appear with particular difficulty 
in differentiating sour and bitter (Epstein 
et al, 2002). In these hyper metabolic 
cancer patients, protein-intake is important 
due to gluconeogenesis, with a loss of lean 
body mass (LBM). This loss of LBM can 
potentially be reduced by protein 
supplements as an integrated part of 
dietary counselling, but it is only shown in 
patients with colorectal cancer undergoing 
radiotherapy (Ravasco et al, 2005). 
However, poor compliance often results in 
patients not reaching their nutritional goals 
(Ravasco, 2005), and part of this are taste-
related problems. Nutritional supplements 
are developed in an industrial setting and 
analysis of taste is very often done in a 
laboratory by a censoring panel. This 
setting and these censors are quite 
different from the patients. Patients with 
gastro-intestinal cancers seem to prefer 
fresh-milk-based supplements to UHT milk 
based (Ultra High Temperature) and fruit 
juice based, also during chemotherapy. 
However, vitamins and minerals were 
added to both the UTH-milk based and the 
fruit based products, and all were 
hyperosmolar (Rahemtulla et al, 2005). No 
similar studies have been published for 
patients with malignant, haematological 
diseases.   
 
This study aimed to determine the patients’ 
preferences for three different ONS 
including non-vitamin-enriched and freshly 
made products. We wanted to examine 
taste perception, and to assess the 
reproducibility of the taste assessments by 
means of a Visual Analogue Scale (VAS) in 





VAS (Visual Analogue Scale) 
 
The reproducibility of VAS is relatively well 
documented in other scientific areas and is 
described as a valid measure of subjective 
phenomenon, but carries a 
phenomenological problem with an 
underlying acceptance of linearity, which 
might not be true (Rødbotten, 1997). In 
this study a unipolar continuous scale was 
used to evaluate the sensory variables: 
sweet, sour, bitter, salt, thickness, gritty 
and metal and the palatability (the ability 
to drink a glass of the product (150 ml)). 
All the VAS-scores were performed 
immediately after tasting, and at the end of 
the experiment patients rated the three 
(four) products 1-3(4), as one was 
repeated. 
  
Selection of Products 
 
Three milk-based products were selected, 
as these were the three mostly used 
products in the department: Nutridrik® 
from Nutricia, Koldskål (RH) from the 
kitchen in Rigshospitalet and Protin® from 
Arla. The products had the same flavour, 
Vanilla and had similar protein content 
(Nutridrik® 6g/100ml, Protin® 
5.7g/100ml and RH 5 g/100ml). 
Nutridrik® is a UHT milk based, 
hyperosmolar product from Nutricia with 
added vitamins and minerals with an 
osmolarity of 450 mOsm/l (in 100 ml: 630 
kJ, 18.4 g carbohydrate, 5.8 g fat). RH is a 
fresh cold buttermilk based product with 
eggs made in the Kitchen on Rigshospitalet 
from day to day. The recipe for one litre is: 
Junket 3 dl, buttermilk 6 dl, egg-yolk 80 g, 
sugar 45 g, and the osmolarity is 653 
mOsm/l. Junket, egg and buttermilk is 
whippet, sugar is added and the taste is 
adjusted with vanilla sugar and lemon (in 
100 ml: 356 kJ, 9.3 g carbohydrate, 3.1 g 
fat).  Protin® is a fresh milk based product 
with added milk-proteins from the diary, 
Arla with a shelf life of 10 days (open 3 
days), osmolarity 718 mOsm/l (in 100 ml: 




The products were served in a plastic cup 
(4 ml) at room temperature in a random 
rotating order on the same day. The 
patients were blinded to the products. The 
samples were served according to a 
preformed protocol with random allocation 
of the drinks, and the repeated drink in a 
random position in the sequence. One of 
the samples was repeated in every 
experiment to quantitate reproducibility. 
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Viscosity 
 
The viscosity was determined by the 
Laboratory of Rheology and Texture, The 
department of Food Technology, The 
Technical University of Denmark by the 
shear stress/shear rate (Pa s). Shear stress 
is the force that moves the liquid, and shear 




Forty-one patients from the haematological 
clinic in Rigshospitalet participated in the 
study (table 1). Patients were asked for 
participating consecutively on rounds if 
they fulfilled the inclusion criteria. 
Inclusion criteria: patients in treatment in 
one of the four haematological units, no 
distinction for cancer type, gender or type 
of treatment. The time interval from the 
last chemotherapy or radiation therapy 
varied from two weeks to two months. All 
the patients had severe eating problems at 
the time of investigation, and all had 
mucositis visually diagnosed. All patients 
were of legal age and mentally able to 
understand written and verbal 
information. Exclusion criteria: use of 
parenteral nutrition or tube feeding, lack of 
ability to communicate and/or cooperate. 
All patients gave written consent. 
 
The protocol was approved by the regional 
ethical committee. 
 
Table 1: Baseline characteristics for 41 patients with 
haematological malignant disease and mucositis. 
 
Number of subject 41 SD/range 
Age 53 years 34-70 
Weight 74.5 kg 17.8 kg 
Height 175.4 cm 10.96 cm 
BMI 24.1 4.87 
Diagnosis   
Leukaemia 26  
Multiple myeloma 8  
Myelofibrosis 1  
TTP 1  
Non-Hodgkin-lymphoma 2  
Uncertain diagnosis 3  
Previous Treatment   
Cytostatic 10  
Stem cell treatment 2  
Transplantation 7  
GVH (graft versus host) 1  
Blood transfusion 1  
Medicine adjustment 8  
Radiation 2  







The patients’ median and average VAS scores for the 3 drinks were similar (table 2),  
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Table 2: Average and median score of the sensory variables for Protin, RH and 
Nutridrik. The numbers are in cm measured on a 10 cm VAS scale. Sensory 
parameters 0: Too much of the variable, 10: Too little of the variable. Drink a 
glass 0: Not alt all, 10: No problem. In 41 patients with haematological 
malignant disease 
 
Product Bitter A glass Sweet Gritty Metal Salt Sour Thickness 
Protin 
n=58 
        
Average 7.9 6.7 4.5 8.0 7.6 8.1 6.8 4.5 
Median 8.6 7.6 4.6 7.8 7.8 8.3 7.6 4.9 
Nutridrik 
n=54 
        
Average 7.4 4.7 3.7 7.5 6.6 7.7 7.6 4.9 
Median 7.9 4.8 3.7 7.9 6.5 8 8.2 4.9 
RH n=52         
Average 7.1 6.6 4.6 7.4 7.3 7.4 6.1 4.6 
Median 7.6 7.1 4.8 7.5 8.1 7.7 5.4 5.0 
 
Without significant difference between the 
three products concerning the sensory 
variables sour and sweet (table 3). There 
was significant difference concerning the 
sensory variables of the three products 
(table 3).  
 
 
Table 3:  Result of Kruskal-Wallis test of the sensory variables for the three 
protein containing drinks in 41 patients with malignant haematological disease 
 
  Bitter A glass Sweet Gritty Metal Salt Sour Thickness 
Chi2 1.410 11.942 6.489 1.933 2.320 2.198 6.786 0.213 
Df 2 2 2 2 2 2 2 2 
 P 0.494 0.003 0.039 0.381 0.314 0.333 0.0336 0.899 
 
 
The taste characteristics are shown in 
figure 1. The differences in sweet, sour and 
sensory variables are illustrated. The VAS 
evaluation of the three products as a hole 
was not markedly different; their spider 
web had similar looks. We found no 
systematic relation between the VAS 
evaluations and the time passed from the 
preceding therapeutic session.  
 























Figure 1: Nutritional supplements - Taste preferences divided in categories in patients 
with malignant haematological disease during active treatment with chemotherapy. 
Spider web of the sensory variables (Bitter, a glass, gritty, metal, salt, sour, sweet and 
thickness) for three products (Protin, Nutridrik and RH (= a fresh cold buttermilk based 
product produced in the hospital) in 41 patients with haematological malignant disease. 
Sensory parameters:  0: Too much of the sensory variable. 10: Too little of the sensory 
variable. Acceptability - Drink a glass:   0: Not at all   10: No problem 
 
The sensory differences of the three 
products  
 
The results were detailed further (table 4). 
The patients judged that Nutridrik® had a 
significant sweeter taste than Protin® 
(p=0.041) and RH (p=0.021); the patients 
liked Protin® (p=0.002) and RH (p=0.005) 
significantly better than Nutridrik®. The 
patients judged that RH (p=0.008) had a 
significantly more sour taste than 
Nutridrik®. No significant differences were 
found between Protin® and RH with 
regard to any of the sensory variables.  
 
Table 4:  Result of Mann-Whitney test for sour, sweet and the ability to ingest a 
glass of 150 ml of the drink in 41 patients with 
 haematological malignant disease. 
 
 Sensory variables 
  A glass  Sweet  Sour  
Protin vs. Nutridrik  p=0.002  p=0.041  p=0.192  
Protin vs. RH  p=0.741  p=0.598  p=0.205  










Gry Bjerg Petersen and Jens Rikardt Andersen (2015), JMED Research, DOI: 10.5171/2015.175008 
Preferences (which drink do you prefer?) 
 
The patients had a significantly higher 
preference for Protin® compared to RH 
and especially to Nutridrik®: Protin® vs. 
Nutridrik® (p< 0.001), Protin® vs. RH 
(p=0.049) and RH vs. Nutridrik® 
(p=0.008).  
 
Ability to drink 150 ml (how difficult is it to 
drink one glass = 150 ml?) 
Patients VAS-scored a significantly higher 
ability to drink 150 ml of Protin® and RH 




Identical (+/- 10% in cm) VAS-score was 
seen in 39 of the 41 patients (95%), when 
blindly testing the same sample twice in 





The difference between the fresh milk 
products (Protin® and RH) and the 
commercial (Nutridrik®) was marked 
(Table 5 and fig 2).
 
Table 5:  Viscosity measurements in milk-based oral, protein-enriched supplements. 
Nutridrik is a commercial drink with added minerals and vitamins, Protin is milk with 
added whey-protein and RH is buttermilk with eggs. The trendlines are shown in fig. 2. n 
and m are the indices of the powerlaw model with m as the general viscosity. N<1 means 












Figure 2: Nutritional supplements – Viscosity determinations. Shear stress (Pa) is the 
force that moves the liquid. Shear rate (1/s) is the velocity gradient. The difference in 
profile is marked between the commercial, milk-based Nutridrink and the fresh milk 




As results were distributed very skew, non-
parametric methods were applied, 
Wilcoxon-, Mann-Whitney rank-sum tests, 
and Kruskal-Wallis test. 
Discussion 
 
Dysgeusia associated with weight loss due 
to lack of appetite and altered eating 
pattern influence the patient’s Quality of 
life. Dysgeusia is caused by many factors, 
  Trendline R2 n SD m SD 
RH y=0.43x + 0.05 0.995 0.400 0.020 1.205 0.090 
Protin y=0.52x - 0.24 0.996 0.516 0.005 0.655 0.113 
Nutridrik y=1.05x - 1.58 1 1.045 0,002 0.024 0.002 





Gry Bjerg Petersen and Jens Rikardt Andersen (2015), JMED Research, DOI: 10.5171/2015.175008 
and simple studies of individual taste 
sensitivity using single taste stimuli (sweet, 
sour, salt, umami or bitter) are not 
considered predictive of dysgeusia nor of 
food aversions (Settle et al, 1978). The 
patients’ preferences for fresh (no UHT) 
milk-based products (Protin and RH) are 
similar to results found in other studies. 
Rahemtulla et al (2005) found no 
significant difference in preference for 
nutritional supplement due to disease or 
cytostatic treatment of 47 patients with 
gastrointestinal cancer and 47 healthy 
controls. Both groups had a preference for 
“Calshake”, a fresh milk based product (No 
UHT) with strawberry flavour. Comparable 
results were reported by Darmon et al 
(2008) testing 109 malnourished in-
patients, who preferred milk-based 
supplements to sweet and salty fruit-juice 
typed products. In a study of 60 patients 
with colorectal cancer using single taste-
stimuli, Kucz et al found a reduced 
sensitivity of taste compared to healthy 
controls (Kucz et al, 2008). This would 
indicate that cancer patients might prefer 
strongly flavoured foods. However, our 
results did not confirm such a hypothesis. 
Pelvic radiotherapy did not markedly affect 
supplement preference in a case-control 
study with healthy controls, but only 28% 
of the cancer patients received concomitant 
chemotherapy (McGough et al, 2006). In 
our setting, we found no systematic 
influence of the time-interval from the last 
chemotherapy or radiation therapy, but all 
the patients had mucositis. Even though 
individual differences in taste perception 
are many and complicated (Stevens, 1996), 
and despite the complex effects of disease, 
dissemination of disease, and treatment 
(Hutton et al, 2007), results seem to have 
some uniform directions. Fresh, milk based 
products seem to have a higher 
acceptability, but agreement is not 
complete. Several explanations might 
contribute. We know that hyperosmolarity 
is a problem for patients with mucositis, 
but all three drinks in our experiment were 
considerably hyperosmolar, making this 
factor an unlikely explanation. Texture was 
also markedly different (fig 2). Whether 
this is a determining factor or not cannot 
be answered with our present knowledge, 
but the enriched milk and the buttermilk-
drink were very similar, and they were 
both evaluated as positive by the patients. 
Nutridrink showed different results, and 
was evaluated very negative. This may 
indicate that texture could be part of an 
explanation. We tried to interview the 
patients for details related to their own 
scoring, but gave it up, as most patients felt 
too tired after the testing sessions. Smell 
and viscosity as well as other textural 
variables could be factors involved. 
 
The advantages of the commercial “full-
nutritional” drinks are their content of 
micronutrients, their very long shelf-life, 
and the control procedures related to the 
manufacturing. The micronutrients might 
well be the reason for the reduced 
palatability, but future studies are needed 
to elucidate this. 
 
All the published studies about taste 
disturbances in patients with malignant 
diseases are single meal tests. In the future, 
we would need long time studies using the 
results from the meal-studies to elucidate 
whether there are positive effects on 
nutritional status during the course of 
treatment, as compliance in the long run is 
determining the clinical value. Weight as 
well as body composition and quality of life 




This study gives an indication of patients’ 
preference with significant higher 
preference and palatability for fresh milk 
products than a commercial, milk based 
product. However, the basic sensory 
parameters studied with VAS gave no clear 
distinction between the three products, 
and the underlying basis for the preference 
is not obvious, and merits further 
investigations. The used test-method was 
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